Company Profile

Viropro, Inc. is engaged in the development and manufacturing of biopharmaceutical drugs. The Company conducts operations primarily through its subsidiary, Alpha Biologics Sdn Bhd (Alpha) located in Penang, Malaysia. The Company intends to offer solution to the biopharma industry from drug concept through to product manufacturing. The Alpha facility consists of approximately 50,000 square feet of research and production space. The Alpha facility is designed to support the scale-up and manufacture of monoclonal antibodies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time OTC Markets 22:40:24 19/10/2021 +04			5-day change	1st Jan Change
0.000500 ^USD	+400.00%		+400.00%	+1,983.33%

27/09/16	Viropro Inc. Announces Resignation of Kenneth Sorensen as Board of Director	CI
04/05/16	Viropro Seeks Acquisitions	CI

27/09/16	Viropro Inc. Announces Resignation of Kenneth Sorensen as Board of Director	CI
04/05/16	Viropro Seeks Acquisitions	CI
02/05/16	Viropro Inc. Announces Executive Changes	CI
02/05/16	Viropro Inc. cancelled the acquisition of NovaRx Corporation.	CI
25/04/16	Viropro Inc. Announces Board Changes	CI
21/04/16	Viropro Inc. Announces the Resignation of John Doll from Board of Directors	CI
11/02/16	Viropro, Inc. Announces Appointment of John Doll to Board of Directors	CI
23/01/16	Viropro Inc. Announces Executive Changes	CI
08/12/15	Viropro, Inc. Names Ivor Royston to its Board of Directors	CI
22/10/15	Viropro Inc. signed a Letter of Intent to acquire NovaRx Corporation	CI
02/02/15	Viropro Announces Plan for Restructuring	CI
25/08/14	Viropro Inc. announced that it has received $0.2 million in funding from SpringHill Bioventures Sdn Bhd.	CI
03/06/14	Viropro Inc. Announces Executive Changes	CI

02/05/16	Viropro : May 2, 2016 -- Letter of Intent to Acquire NovaRx Expires; Viropro Appoints New Slate of Officers	PU
02/05/16	Viropro : Letter of Intent to Acquire NovaRx Expires; Viropro Appoints New Slate of Officers	PR
08/12/15	Viropro : December 8, 2015 -- Dr. Ivor Royston, Oncologist, Entrepreneur, Investor and a Founder of San Diego Biotech, Joins Viropro Board	PU
23/10/15	Viropro : October 22, 2015 -- Viropro Announces Signing of Letter of Intent to Acquire NovaRx	PU
09/10/15	Viropro : October 9, 2015 -- Viropro Announces Appointment of Ciro E. Adams, CPA, LLC, as New Audit Firm, Secures Additional $200,000 in Convertible Debt	PU

1 day	+400.00%
1 week	+400.00%
Current month	+400.00%
1 month	+400.00%
3 months	+400.00%
6 months	+49,900.00%
Current year	+1,983.33%

Viropro Inc. Stock

Stocks

VPRO

US9282422057

Biotechnology & Medical Research

Latest news: Viropro Inc.

Press Releases: Viropro Inc.

Quotes and Performance

Price Extremes

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIROPRO INC.	+400.00%	+400.00%	+1,983.33%	+49,900.00%	127K
WUXI APPTEC CO., LTD.	+4.16%	-0.36%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.61%	+0.81%	+27.25%	+80.21%	60.14B
LONZA GROUP AG	-2.54%	-1.65%	+4.86%	+33.32%	48.15B
IQVIA HOLDINGS INC.	-2.88%	-4.81%	+28.47%	+35.03%	44.25B
REVOLUTION MEDICINES, INC.	+0.93%	+3.72%	+352.03%	+692.13%	43.99B
BEONE MEDICINES AG	-1.76%	+0.06%	+7.47%	+101.79%	41.61B
CELLTRION, INC.	+3.32%	+3.49%	+11.18%	+51.23%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	-3.69%	-9.62%	-25.41%	+333.01%	24.93B
Average	+40.17%	+1.77%	+247.53%	+5,134.37%	39.68B
Weighted average by Cap.	+0.36%	+1.83%	+58.94%	+151.68%

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0
10 years	0		0.01